For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Lebanon: A recent study analyzing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has ...

A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Weight loss drug Wegovy uses the same drug as Ozempic, called semaglutide, and has been licensed for use in the UK. Wegovy ...

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...